SCHEMBL3873274

SCHEMBL3873274

COC(=O)c1cccc(CNS(=O)(=O)c2cccc(Cl)c2C)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.49
NAMPT P43490 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
PFKFB3 Q16875 1/20 0.46
PFKFB4 Q16877 1/20 0.46
TP53 P04637 1/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HIF1A Q16665 1/20 0.44
GAA P10253 1/20 0.43
CYP19A1 P11511 2/20 0.43
AQP1 P29972 1/20 0.43
POLB P06746 1/20 0.43
MRGPRX4 Q96LA9 3/20 0.43
GPR17 Q13304 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884734 0.89 MAPT (0.51) FABP4NAMPTMAPTALDH1A1POLB
SCHEMBL3874145 0.88 FABP4 (0.56) FABP4TP53GAACYP19A1POLB
SCHEMBL3876675 0.83 HSD11B1 (0.53) FABP4TP53MAPTALDH1A1GAA
SCHEMBL3873411 0.80 PFKFB3 (0.48) PFKFB3PFKFB4TP53MAPTALDH1A1
SCHEMBL3872847 0.80 TP53 (0.48) LOXL2CYP4F2CYP4A11PFKFB3PFKFB4
SCHEMBL3872896 0.79 LMNA (0.52) TP53MAPTALDH1A1GAAPOLB
SCHEMBL3876258 0.79 HSD11B1 (0.56) MAPTALDH1A1
SCHEMBL3872261 0.78 ALDH1A1 (0.56) MAPTALDH1A1POLB
SCHEMBL4176458 0.78 LMNA (0.57) TP53MAPTALDH1A1GAACYP19A1
SCHEMBL7573034 0.76 ACLY (0.53) PFKFB3PFKFB4TP53MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed
EP-1655283-A1 11beta-HSD1 Inhibitors Evotec OAI AG (DE) 2006-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 FABP4 1873/4885NAMPT 2223/4885LOXL2 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.